SMARCA1 and neoplasm: CARM1i have the potential for specifically targeting the oncogenic functions of SWI/SNF by both preventing the redistribution of this remodeling complex to genes involved in the c-Myc pathway and reducing the activity of tumor-associated super-enhancers.